Chronic Kidney Disease and Multiple Myeloma Case in Clinical Nephrology

Year 2020, Volume: 6 Issue: 1, 135 - 138, 30.04.2020

Ahmet Karataş , Burcu Ülkü Mervegül Kaya Aykut Özturan

https://doi.org/10.19127/mbsjohs.694541

Abstract

Multiple myeloma (MM) is a neoplastic plasma cell dyscrasia identify by anemia, recurrent infections, increased serum and / or monoclonal protein in urine, osteolytic bone lesions, hypercalcemia and renal failure. MM accounts for approximately 1% of all cancer cases and 10% of hematological malignancies MM related renal failure is an important prognostic factor leading to early mortality and ranges from 20-50% depending on the frequency of kidney disease in MM. In the present paper, we report that advanced age, concomitant chronic renal failure with unknown cause and anemia should always bring MM to mind; In these cases, serum and urine immunization electrophoresis should be requested even if serum protein electrophoresis is normal.

Keywords

Light chain, multiple myeloma, immunofixation

References

• Alexandrakis MG, Passam FH, Ganotakis ES, Sfiridaki K, Xilouri I, Perisinakis K, et al. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma. Clin Lab Haematol 2003; 25 (1): 41-6.
• Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990; 150 (8): 1693-5.
• Barlogie B, Shaughnessy J, Epstein J, et al. Williams Hematology. 7th ed. USA: Mc Graw Hill Companies; 2006
• Blade J, Rosinol L. Renal, hematologic and infectious complications in multiple myeloma. Best Pract Res Clin Haematol 2005; 18 (4): 635-52.
• Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 2007; 48 (2): 337-41.
• Hillengass J, Usmani S, Rajkumar SV, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 2019;20:e302-e12
• Jones HB. On a new substance occuring in the urine of a patient with mollities ossium. Philos Trans R Soc Lon 1848; 138: 55-62
• Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78 (1): 21- 33
• Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ, 3rd. Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades. Cancer 2004;101:2667-74.
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. Lancet Oncol 2014;15:e538-48.
• Rajkumar SV. Multiple Myeloma: 2020 update on Diagnosis, Risk-stratification, and Management. Am J Hematol. 2020 Mar 24. doi: 10.1002/ajh.25791
• Roodman GD. Pathogenesis of myeloma bone disease. Leukemia 2009;23:435-41
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30
• Torra R, Blade J, Cases A, et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91 (4): 854-9.
• Winearls CG. Acute myeloma kidney. Kidney Int 1995; 48 (4): 1347-61.